Literature DB >> 11118039

Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.

M Sumitomo1, R Shen, J S Goldberg, J Dai, D Navarro, D M Nanus.   

Abstract

Phorbol esters induce apoptosis in androgen-sensitive LNCaP cells, which express neutral endopeptidase (NEP), but not in androgen-independent prostate cancer (PC) cells, which lack NEP expression. We investigated the role of NEP in PC cell susceptibility to 12-O-tetradecanoylphorbol-13-acetate (TPA). Western analysis showed that expression of NEP and protein kinase Cdelta (PKCdelta) correlated with PC cell sensitivity to TPA-induced growth arrest and apoptosis in LNCaP cells and in TSU-Prl cells expressing an inducible wild-type NEP protein. Inhibition of NEP enzyme activity using the specific NEP inhibitor CGS24592, or inhibition of PKCdelta using Rottlerin at concentrations that inhibit PKCdelta but not PKCalpha, significantly inhibited TPA-induced growth inhibition and cell death. Furthermore, pulse-chase experiments showed PKCdelta is stabilized in LNCaP cells and in TSU-Pr1 cells overexpressing wild-type NEP compared with PC cells lacking NEP expression. This results from NEP inactivation of its neuropeptide substrates (bombesin and endothelin-1), which in the absence of NEP stimulate cSrc kinase activity and induce rapid degradation of PKCdelta protein. These results indicate that expression of enzymatically active NEP by PC cells is necessary for TPA-induced apoptosis, and that NEP inhibits neuropeptide-induced, cSrc-mediated PKCdelta degradation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells.

Authors:  Makoto Sumitomo; Motoi Ohba; Junichi Asakuma; Takako Asano; Toshio Kuroki; Tomohiko Asano; Masamichi Hayakawa
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

4.  Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

Authors:  June G Lee; Rong Zheng; Jennifer M McCafferty-Cepero; Kerry L Burnstein; David M Nanus; Ruoqian Shen
Journal:  Mol Carcinog       Date:  2009-02       Impact factor: 4.784

5.  Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.

Authors:  Jin Zhu; Jun Y Gong; Oscar B Goodman; Luca Cartegni; David M Nanus; Ruoqian Shen
Journal:  Biochim Biophys Acta       Date:  2007-05-03

6.  Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.

Authors:  Katsuyuki Iida; Rong Zheng; Ruoqian Shen; David M Nanus
Journal:  Int J Oncol       Date:  2012-08-08       Impact factor: 5.650

7.  Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression.

Authors:  L A Dawson; N J Maitland; A J Turner; B A Usmani
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

Review 8.  Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Authors:  Thenappan Chandrasekar; Joy C Yang; Allen C Gao; Christopher P Evans
Journal:  Transl Androl Urol       Date:  2015-06

9.  Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.

Authors:  Chieh-Yang Cheng; Zongxiang Zhou; Meredith Stone; Bao Lu; Andrea Flesken-Nikitin; David M Nanus; Alexander Yu Nikitin
Journal:  Oncogenesis       Date:  2020-03-23       Impact factor: 7.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.